Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 Expressing Solid Tumors

2023-508808-38-00 Protocol CDR404-001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 29 May 2024 · Status Ongoing, recruiting · 4 EU/EEA countries · 13 sites · Protocol CDR404-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 100
Countries 4
Sites 13

Solid tumors

Key facts

Sponsor
CDR-Life AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
29 May 2024 → ongoing
Decision date (initial)
2024-06-28
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-508808-38-00
WHO UTN
U1111-1299-0120

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Solid tumors

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

CDR-Life AG

Sponsor organisation
CDR-Life AG
Address
Todistrasse 46
City
Horgen
Postcode
8810
Country
Switzerland

Scientific contact point

Organisation
CDR-Life AG
Contact name
Clare Price

Public contact point

Organisation
CDR-Life AG
Contact name
Clare Price

Locations

4 EU/EEA countries · 13 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruiting 15 4
Denmark Ongoing, recruiting 10 1
Italy Ongoing, recruiting 13 2
Spain Ongoing, recruiting 20 6
Rest of world
United States
42

Investigational sites

Belgium

4 sites · Ongoing, recruiting
Cliniques Universitaires Saint-Luc
Oncology, Hippokrateslaan 10, Batiment 54, Sint-Lambrechts-Woluwe
Universitair Ziekenhuis Gent
Oncology, Corneel Heymanslaan 10, 9000, Gent
Institut Jules Bordet
Oncology, Mijlenmeersstraat 90, 1070, Anderlecht
Antwerp University Hospital
Oncology, Drie Eikenstraat 655, 2650, Edegem

Denmark

1 site · Ongoing, recruiting
Rigshospitalet
Oncology, Blegdamsvej 9, 2100, Copenhagen Oe

Italy

2 sites · Ongoing, recruiting
Istituto Europeo Di Oncologia S.r.l.
Oncology, Via Giuseppe Ripamonti 435, 20141, Milan
Humanitas Mirasole S.p.A.
Oncology, Via Alessandro Manzoni 56, 20089, Rozzano

Spain

6 sites · Ongoing, recruiting
Vall D'hebron Institut De Recerca
Oncology, Passeig De La Vall D'hebron 119-129, 08035, Barcelona
Hospital Universitario 12 De Octubre
Oncology, Bloque D, Avenida De Cordoba Sn, Madrid
Institut Catala D'oncologia
Oncology, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Hospital Universitario Hm Sanchinarro
Oncology, Calle Ona 10, 28050, Madrid
Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA
Oncology, Avenida Menendez Y Pelayo 4, 46010, Valencia
Hospital Universitario Y Politecnico La Fe
Oncology, Avenida De Fernando Abril Martorell 106, 46026, Valencia

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2024-10-02 2024-10-08
Denmark 2024-05-29 2024-08-02
Italy 2025-01-28 2025-01-29
Spain 2024-12-17 2024-12-26

Application history

10 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-01-24 Denmark Acceptable
2024-04-26
2024-04-28
2 SUBSEQUENT ADDITION OF MSC APP-2 2024-05-10 2024-06-28
3 SUBSEQUENT ADDITION OF MSC APP-3 2024-05-10 Acceptable
2024-04-26
2024-07-31
4 SUBSEQUENT ADDITION OF MSC APP-4 2024-05-10 Acceptable
2024-04-26
2024-06-18
5 SUBSTANTIAL MODIFICATION SM-1 2024-09-06 Denmark Acceptable
2024-11-29
2024-11-29
6 NON SUBSTANTIAL MODIFICATION NSM-1 2025-01-27 Acceptable
2024-11-29
2025-01-27
7 SUBSTANTIAL MODIFICATION SM-2 2025-04-10 Denmark Acceptable
2025-05-28
2025-05-30
8 SUBSTANTIAL MODIFICATION SM-4 2025-09-18 Acceptable 2025-09-26
9 SUBSTANTIAL MODIFICATION SM-5 2025-09-26 Denmark Acceptable
2025-11-06
2025-11-06
10 SUBSTANTIAL MODIFICATION SM-6 2026-01-27 Denmark Acceptable
2026-04-23
2026-04-24